Mylan NV (NASDAQ:MYL) Expected to Post Quarterly Sales of $3.25 Billion

Wall Street analysts expect that Mylan NV (NASDAQ:MYL) will post sales of $3.25 billion for the current quarter, according to Zacks Investment Research. Four analysts have made estimates for Mylan’s earnings, with estimates ranging from $3.20 billion to $3.28 billion. Mylan reported sales of $3.08 billion during the same quarter last year, which would suggest a positive year-over-year growth rate of 5.5%. The business is expected to issue its next earnings results on Tuesday, February 25th.

According to Zacks, analysts expect that Mylan will report full year sales of $11.56 billion for the current financial year, with estimates ranging from $11.50 billion to $11.59 billion. For the next financial year, analysts expect that the company will report sales of $11.99 billion, with estimates ranging from $11.82 billion to $12.17 billion. Zacks’ sales calculations are a mean average based on a survey of sell-side research analysts that that provide coverage for Mylan.

Mylan (NASDAQ:MYL) last posted its quarterly earnings data on Tuesday, November 5th. The company reported $1.17 EPS for the quarter, beating the consensus estimate of $1.14 by $0.03. The business had revenue of $2.96 billion for the quarter, compared to analysts’ expectations of $3.01 billion. Mylan had a net margin of 0.42% and a return on equity of 18.80%. The firm’s revenue was up 3.5% compared to the same quarter last year. During the same period in the previous year, the firm posted $1.25 EPS.

MYL has been the subject of several recent research reports. Morgan Stanley cut Mylan from an “overweight” rating to an “equal” rating and reduced their price objective for the stock from $25.00 to $18.00 in a research report on Thursday, November 7th. SunTrust Banks lifted their target price on Mylan from $25.00 to $27.00 and gave the company a “buy” rating in a research report on Thursday, September 12th. BidaskClub raised Mylan from a “sell” rating to a “hold” rating in a research report on Thursday, November 28th. Cfra upgraded Mylan to a “hold” rating in a research note on Wednesday, November 27th. Finally, ValuEngine raised Mylan from a “strong sell” rating to a “sell” rating in a research report on Wednesday, October 2nd. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating and eleven have assigned a buy rating to the company. The company presently has an average rating of “Buy” and a consensus target price of $27.97.

MYL opened at $19.29 on Monday. The business’s 50-day moving average price is $18.31 and its two-hundred day moving average price is $18.86. Mylan has a 1 year low of $16.63 and a 1 year high of $32.23. The company has a market capitalization of $9.75 billion, a price-to-earnings ratio of 4.21, a P/E/G ratio of 1.02 and a beta of 1.71. The company has a debt-to-equity ratio of 1.17, a current ratio of 1.43 and a quick ratio of 0.84.

In other news, insider Goulds Bruce 8,000,000 shares of the business’s stock in a transaction that occurred on Friday, November 8th. Corporate insiders own 0.81% of the company’s stock.

A number of hedge funds have recently made changes to their positions in MYL. Advisory Services Network LLC raised its holdings in shares of Mylan by 170.0% in the 2nd quarter. Advisory Services Network LLC now owns 1,520 shares of the company’s stock valued at $29,000 after purchasing an additional 957 shares during the period. Rational Advisors LLC grew its holdings in Mylan by 1,111.0% during the second quarter. Rational Advisors LLC now owns 2,192 shares of the company’s stock worth $42,000 after purchasing an additional 2,011 shares during the period. Steward Partners Investment Advisory LLC grew its holdings in Mylan by 92.9% during the third quarter. Steward Partners Investment Advisory LLC now owns 2,367 shares of the company’s stock worth $46,000 after purchasing an additional 1,140 shares during the period. CSat Investment Advisory L.P. increased its position in Mylan by 258.9% during the second quarter. CSat Investment Advisory L.P. now owns 2,835 shares of the company’s stock worth $54,000 after buying an additional 2,045 shares during the last quarter. Finally, Parallel Advisors LLC increased its position in Mylan by 570.7% during the third quarter. Parallel Advisors LLC now owns 2,998 shares of the company’s stock worth $59,000 after buying an additional 2,551 shares during the last quarter. Hedge funds and other institutional investors own 86.54% of the company’s stock.

Mylan Company Profile

Mylan N.V., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic, branded-generic, brand-name, and over-the-counter (OTC) pharmaceutical products in North America, Europe, and internationally. It offers active pharmaceutical ingredients and finished dosage forms; and antiretroviral medicines to treat HIV/AIDS.

Read More: Are FAANG stocks a good investment?

Get a free copy of the Zacks research report on Mylan (MYL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Mylan (NASDAQ:MYL)

Receive News & Ratings for Mylan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mylan and related companies with MarketBeat.com's FREE daily email newsletter.